Literature DB >> 21674518

An interactive voice response diary for patients with non-dystrophic myotonia.

Jeffrey M Statland1, Yunxia Wang, Rachel Richesson, Brian Bundy, Laura Herbelin, Joe Gomes, Jaya Trivedi, Shannon Venance, Anthony Amato, Michael Hanna, Robert Griggs, Richard J Barohn.   

Abstract

INTRODUCTION: Non-dystrophic myotonia (NDM) is caused by mutations in muscle chloride and sodium channels. Currently, there is no standardized instrument for documenting symptom frequency and severity in NDM.
METHODS: Subjects used an automated, interactive, telephone-based voice response diary (IVR) to record frequency and severity of stiffness, weakness, pain, and tiredness once a week for 8 weeks, after their baseline visits.
RESULTS: We describe the IVR and report data on 76 subjects for a total of 385 person-weeks. Overall there were 5.1 calls per subject. Forty-eight subjects called in 5 or more times, and 14 called in 8 times. Stiffness was both the most frequent and severe symptom. Warm-up and handgrip myotonia were associated with higher severity scores for stiffness.
CONCLUSIONS: IVR is a convenient technology to allow patient reporting of repeated and real-time symptom frequency and severity, and it is presently being used in a trial of mexiletine in NDM.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21674518      PMCID: PMC3233757          DOI: 10.1002/mus.22007

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

1.  Patient non-compliance with paper diaries.

Authors:  Arthur A Stone; Saul Shiffman; Joseph E Schwartz; Joan E Broderick; Michael R Hufford
Journal:  BMJ       Date:  2002-05-18

Review 2.  Genetics and physiology of the myotonic muscle disorders.

Authors:  L J Ptacek; K J Johnson; R C Griggs
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245

Review 3.  The familial periodic paralyses and nondystrophic myotonias.

Authors:  L Ptácek
Journal:  Am J Med       Date:  1998-07       Impact factor: 4.965

4.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

Review 5.  Phenotypic variability in myotonia congenita.

Authors:  Eskild Colding-Jørgensen
Journal:  Muscle Nerve       Date:  2005-07       Impact factor: 3.217

Review 6.  Myotonic dystrophy type 2 and related myotonic disorders.

Authors:  Giovanni Meola; Richard T Moxley
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

7.  Redefining the clinical phenotypes of non-dystrophic myotonic syndromes.

Authors:  J Trip; G Drost; H B Ginjaar; F H M Nieman; A J van der Kooi; M de Visser; B G M van Engelen; C G Faber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-11       Impact factor: 10.154

8.  Treatment of myotonia with antiarrhythmic drugs.

Authors:  H Kwieciński; B Ryniewicz; A Ostrzycki
Journal:  Acta Neurol Scand       Date:  1992-10       Impact factor: 3.209

Review 9.  Treatment of neuromuscular channelopathies: current concepts and future prospects.

Authors:  James C Cleland; Robert C Griggs
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

10.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors: 
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

View more
  12 in total

1.  Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.

Authors:  Bas C Stunnenberg; Joost Raaphorst; Hans M Groenewoud; Jeffrey M Statland; Robert C Griggs; Willem Woertman; Dick F Stegeman; Janneke Timmermans; Jaya Trivedi; Emma Matthews; Christiaan G J Saris; Bas J Schouwenberg; Gea Drost; Baziel G M van Engelen; Gert Jan van der Wilt
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

Review 2.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

3.  Mexiletine for treatment of myotonia: a trial triumph for rare disease networks.

Authors:  Eric P Hoffman; Henry J Kaminski
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

Review 4.  Rare neurological channelopathies--networks to study patients, pathogenesis and treatment.

Authors:  Joanna C Jen; Tetsuo Ashizawa; Robert C Griggs; Michael F Waters
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 5.  Interactive voice response technology for symptom monitoring and as an adjunct to the treatment of chronic pain.

Authors:  Gregory Lieberman; Magdalena R Naylor
Journal:  Transl Behav Med       Date:  2012-03       Impact factor: 3.046

6.  Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.

Authors:  Bas C Stunnenberg; Willem Woertman; Joost Raaphorst; Jeffrey M Statland; Robert C Griggs; Janneke Timmermans; Christiaan G Saris; Bas J Schouwenberg; Hans M Groenewoud; Dick F Stegeman; Baziel G M van Engelen; Gea Drost; Gert Jan van der Wilt
Journal:  BMC Neurol       Date:  2015-03-25       Impact factor: 2.474

7.  Analysis of factors influencing telephone call response rate in an epidemiological study.

Authors:  Jorge Matías-Guiu; Pedro Jesús Serrano-Castro; José Ángel Mauri-Llerda; Francisco José Hernández-Ramos; Juan Carlos Sánchez-Alvarez; Marisa Sanz
Journal:  ScientificWorldJournal       Date:  2014-10-21

8.  Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.

Authors:  Jaya R Trivedi; Brian Bundy; Jeffrey Statland; Mohammad Salajegheh; Dipa Raja Rayan; Shannon L Venance; Yunxia Wang; Doreen Fialho; Emma Matthews; James Cleland; Nina Gorham; Laura Herbelin; Stephen Cannon; Anthony Amato; Robert C Griggs; Michael G Hanna; Richard J Barohn
Journal:  Brain       Date:  2013-06-13       Impact factor: 13.501

9.  Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Dipa Raja Rayan; Jaya R Trivedi; Valeria A Sansone; Mohammad K Salajegheh; Shannon L Venance; Emma Ciafaloni; Emma Matthews; Giovanni Meola; Laura Herbelin; Robert C Griggs; Richard J Barohn; Michael G Hanna
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

10.  Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS).

Authors:  Shinichiro Yamada; Atsushi Hashizume; Yasuhiro Hijikata; Tomonori Inagaki; Daisuke Ito; Fumie Kinoshita; Masahiro Nakatochi; Yumiko Kobayashi; Akihiro Hirakawa; Tomohiko Nakamura; Masahisa Katsuno
Journal:  BMJ Open       Date:  2018-09-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.